{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:10:40Z","timestamp":1758039040849,"version":"3.44.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ad.2011.08.014","type":"journal-article","created":{"date-parts":[[2012,5,9]],"date-time":"2012-05-09T11:12:54Z","timestamp":1336561974000},"page":"239-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hepatitis C aguda en un paciente en tratamiento con etanercept"],"prefix":"10.1016","volume":"104","author":[{"given":"M.","family":"Armengot-Carb\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Giner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ad.2011.08.014_bib0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0001-7310(10)70014-4","article-title":"Etanercept e infecci\u00f3n cr\u00f3nica por los virus de la hepatitis C y B","volume":"101","author":"Bordas","year":"2010","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2011.08.014_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.piel.2010.12.002","article-title":"Afectaci\u00f3n hep\u00e1tica biol\u00f3gica en el tratamiento de la psoriasis. Consideraciones pr\u00e1cticas","volume":"26","author":"Llamas-Velasco","year":"2011","journal-title":"Piel"},{"key":"10.1016\/j.ad.2011.08.014_bib0015","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2011.08.014_bib0020","first-page":"645","article-title":"Tumour necrosis factor-\u03b1 antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients","volume":"164","author":"Prignano","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2011.08.014_bib0025","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaad.2009.07.010","article-title":"Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data","volume":"62","author":"Paradisi","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2011.08.014_bib0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2230.2009.03476.x","article-title":"Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection","volume":"35","author":"Behnam","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2011.08.014_bib0035","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/039463201002300335","article-title":"Etanercept therapy in patients with psoriasis and concomitant HCV infection","volume":"23","author":"Garavaglia","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ad.2011.08.014_bib0040","article-title":"Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients","author":"Zanni","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2011.08.014_bib0045","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/ard.2010.139824","article-title":"Successful clearance of hepatitis C virus with pegylated interferon \u03b1-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis","volume":"70","author":"Mederacke","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2011.08.014_bib0050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1600-0676.1996.tb00768.x","article-title":"Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C","volume":"16","author":"Fukuda","year":"1996","journal-title":"Liver"},{"key":"10.1016\/j.ad.2011.08.014_bib0055","first-page":"210","article-title":"Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C","volume":"23","author":"Larrea","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2011.08.014_bib0060","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2011.08.014_bib0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: Management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"J Hepatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173101200110X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173101200110X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:00:05Z","timestamp":1757552405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000173101200110X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S000173101200110X"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2011.08.014","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C aguda en un paciente en tratamiento con etanercept","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2011.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Espa\u00f1a, S.L. and AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}